Pharmacia & Upjohn Linomide Phase III MS trials discontinued due to cardiac events.
Executive Summary
PHARMACIA & UPJOHN LINOMIDE MS PHASE III TRIALS DISCONTINUED April 3 after eight cases of nonfatal myocardial infarction among 1,200 patients, Pharmacia & Upjohn reported. The immunomodulator roquinimex was being studied in three separate trials for treatment of relapsing-remitting and secondary progressive multiple sclerosis. MI cases were observed in two of the three trials.